Biomaterial implants have a long history of clinical use while regenerative medicine strategies have been slow to reach patients. This lecture will summarize the translation of biomaterial technologies originating from the lab for tissue reconstruction in orthopedics and plastic surgery. Clinical translation provides a unique and critical opportunity to investigate the key therapeutic drivers of technology efficacy in people. This (re)evaluation of design parameters is central to improving research and design. A key outcome of our clinical translation experience was the discovery of unexpected adaptive immune cells around implants and recognizing the critical role of the immune system in the biomaterial response and tissue repair outcomes. Today, the lab’s research is focused on defining fundamentals of the immune response to biomaterials, immunoengineering and designing immunotherapies for regenerative medicine.
Dr. Jennifer Elisseeff
Professor and Director, Translational Tissue Engineering Center
Wilmer Eye Institute and Departments of Biomedical Engineering, Orthopedic Surgery, Chemical and Biological Engineering, and Materials Science and Engineering at Johns Hopkins University
Dr. Elisseeff is the Morton Goldberg Professor and Director of the Translational Tissue Engineering Center at Johns Hopkins Department of Biomedical Engineering and the Wilmer Eye Institute with appointments in Chemical and Biological Engineering, Materials Science and Orthopedic Surgery. She received a bachelor’s degree in chemistry from Carnegie Mellon University and a PhD in Medical Engineering from the Harvard–MIT Division of Health Sciences and Technology. She was a Fellow at the National Institute of General Medical Sciences, Pharmacology Research Associate Program, where she worked in the National Institute of Dental and Craniofacial Research. Dr. Elisseeff is committed to the translation of regenerative biomaterials and has founded several companies and participates in several industry advisory boards including the State of Maryland’s Technology Development Corporation (TEDCO). She was elected a Fellow of the American Institute of Medical and Biological Engineering, the National Academy of Inventors, a Young Global Leader by World Economic Forum. In 2018, she was elected to the National Academy of Engineering and National Academy of Medicine. In 2019, she received the NIH Director’s Pioneer Award.